Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Tsai

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
Blood|January 21, 2022
Structural racism is a mediator of disparities in acute myeloid leukemia outcomesIvy Elizabeth Abraham, Garth H Rauscher, Anand Ashwin Patel, et al.
Blood|October 16, 2025
Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical TrialsAndrew Hantel, Yating Wang, Angel Cronin, et al.
Blood|May 19, 2026
Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi StudyLori Muffly, Noelle V Frey, Gregory W Roloff, et al.
Blood Advances|May 7, 2025
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS InvolvementIbrahim N Muhsen, Gregory W Roloff, Rawan G Faramand, et al.
Transplantation and Cellular Therapy|June 27, 2026
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)Rawan G Faramand, Amy Zhang, Gregory W Roloff, et al.
Blood Advances|June 25, 2026
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALLTamer Othman, Gregory W Roloff, Katharine Miller, et al.
Blood Advances|October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemiaYannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood Advances|August 2, 2024
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALLIbrahim Aldoss, Gregory W Roloff, Rawan Faramand, et al.
Bone Marrow Transplantation|August 23, 2025
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemiaTimothy E O'Connor, Chenyu Lin, Gregory W Roloff, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
Blood|January 21, 2022
Structural racism is a mediator of disparities in acute myeloid leukemia outcomesIvy Elizabeth Abraham, Garth H Rauscher, Anand Ashwin Patel, et al.
Blood|October 16, 2025
Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical TrialsAndrew Hantel, Yating Wang, Angel Cronin, et al.
Blood|May 19, 2026
Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi StudyLori Muffly, Noelle V Frey, Gregory W Roloff, et al.
Blood Advances|May 7, 2025
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS InvolvementIbrahim N Muhsen, Gregory W Roloff, Rawan G Faramand, et al.
Transplantation and Cellular Therapy|June 27, 2026
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)Rawan G Faramand, Amy Zhang, Gregory W Roloff, et al.
Blood Advances|June 25, 2026
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALLTamer Othman, Gregory W Roloff, Katharine Miller, et al.
Blood Advances|October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemiaYannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood Advances|August 2, 2024
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALLIbrahim Aldoss, Gregory W Roloff, Rawan Faramand, et al.
Bone Marrow Transplantation|August 23, 2025
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemiaTimothy E O'Connor, Chenyu Lin, Gregory W Roloff, et al.
Pageof 11